Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT06096116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Recruiting
Start date
August 21, 2024
Completion date
March 31, 2028
Enrollment
120 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acquired antithrombin deficiency